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Patients with hepatitis C virus-related decompensated cirrhosis can beneﬁt from interferon-
based  antiviral therapy, but the common complication of cytopenia is a contraindication
for  this treatment. Splenectomy prior to interferon therapy may alleviate this problem. To
investigate whether splenectomy improves the efﬁcacy of antiviral therapy, 13 interferon-
naïve  hepatitis C virus decompensated cirrhotic patients underwent splenectomy between
January  2008 and January 2011, followed 1–3 months later by an interferon-based ther-
apeutic  regimen (pegylated/standard interferon- combined with ribavirin for 48 weeks).
Ten  (76.9%) of the patients developed postoperative complications, which included minor
portal  vein thrombosis (2/13, 15.4%) and transient ascites (8/13, 61.5%). At one-month post-
splenectomy,  the patients showed signiﬁcantly increased platelet (pre-surgery: 48.2 ± 15.9
vs. 186.0 ± 70.6 × 103 L−1, p < 0.001) and leukocyte (2.1 ± 0.5 vs. 5.7 ± 1.4 × 103 L−1, p < 0.001)
counts.  Eight (61.5%) of the patients achieved sustained virological response, including
all  HCV genotype 2a-infected patients (4/4, 100%) and some of the genotype 1b-infected
patients  (4/9, 44.4%). Temporary interferon- suspension was required for one patientto  address severe intestinal infection. These results indicate that splenectomy prior to
interferon-based  therapy was safe and may facilitate adherence to subsequent antiviral
therapy  in selected HCV cirrhotic patients with portal hypertension and hypersplenism.
IFN-based  therapies and some develop contraindications that
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pproximately 170 million people are currently infected
orldwide. Chronic infection is frequent and is strongly asso-
iated  with development of cirrhosis within ∼20 years of the
1riginal  diagnosis. Improvements in antiviral drugs, such as
he pegylated (PEG) form of interferon (IFN), and treatment
egimens, such as the IFN-based combination therapy with
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response (SVR) and improved long-term prognosis.2,3 How-
ever,  not all chronic hepatitis C patients are amenable to thee Second Afﬁliated Hospital, College of Medicine, Xi’an Jiaotong
necessitate  treatment suspension, reduced dosage, or termi-
nation  of therapy.4,5 When the threat of unmitigated chronic
hepatitis C cases was  investigated in a mathematical model of
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Table 1 – Clinical characteristics and therapeutic outcomes of treated patients.
Patient Age/sex Child-Pugh
scorea
Cirrhosis-related
complicationb
Interferon
type/dose
HCV
genotype
HCV RNA,
KIU
Outcome
1 58/F 5 Ascites PEG-IFN-2b/1.5 g/kg 1b 18 SVR
2 44/M 6 Ascites and variceal bleeding PEG-IFN-2a/180 g 1b 14 SVR
3 48/F 7 Ascites and variceal bleeding IFN-2b/3 MU 2a 28 SVR
4 61/F 7 Ascites PEG-IFN-2b/1.5 g/kg 1b 340 Relapse
5 56/F 6 Ascites and SBP PEG-IFN-2a/180 g 1b 168 SVR
6 58/M 6 Ascites and variceal bleeding IFN-2b/3 MU 1b 199 PR
7 39/F 5 Ascites IFN-2b/3 MU 1b 4 Relapse
8 39/F 5 Ascites IFN-2b/3 MU 2a 200 SVR
9 55/F 8 Ascites, SBP, and variceal bleeding IFN-2b/2.1 MU 1b 734 NR
10 62/M 5 Ascites and variceal bleeding PEG-IFN-2b/1.5 g/kg 1b 120 SVR
11 58/F 7 Ascites and variceal bleeding IFN-2b/3 MU 2a 276 SVR
12 49/F 5 Ascites and SBP IFN-2b/3 MU 1b 217 Relapse
13 46/M 5 Ascites and variceal bleeding IFN-2b/3 MU 2a 1100 SVR
PEG-IFN-, pegylated-interferon-alpha; IFN-, interferon alpha; SBP, spontaneous bacterial peritonitis; SVR, sustained virological response; PR,
partial response; NR, null response.
a Child-Pugh score before splenectomy.
b Clinical complications experienced before study enrollment.
the disease’s natural progression, researchers predicted a dra-
matic  increase in the number of HCV-related cirrhotic cases
over  the next two decades.6
Liver cirrhosis is the manifestation of structural changes
in  the liver tissue, such as ﬁbrotic deposition and scarring,
which occur as a result of long-term liver disease. Once the
structural  damage comprises ∼80% of the organ, the liver cir-
rhosis  progresses to the decompensated stage when the liver
is  no longer able to function properly. Decompensated cirrho-
sis  patients have a very high frequency of hospital admission,
a  generally low quality of life, and high risk of mortality.4
Liver transplantation remains the only successful therapeu-
tic  option for these patients, but the limited number of organ
donors  and high expense severely restricts its applicabil-
ity.
Investigators aiming to identify feasible and efﬁcacious
therapies for patients with HCV-related compensated and
decompensated cirrhosis have observed beneﬁcial results
from  IFN--based antiviral therapy.3,4,7 Unfortunately, a large
proportion of these patients have preexisting neutropenia,
thrombocytopenia, and anemia that tend to worsen with
the  use of IFN and ribavirin and necessitate dose reduction
or  treatment discontinuation.4,5 In addition, some patients
present with severe baseline thrombocytopenia and leuko-
cytopenia  due to hypersplenism that preclude initiation
of  IFN-based therapy. New non-IFN therapeutic approaches
using  combinations of direct-acting antiviral agents (DAAs)
with  or without ribavirin have been developed. While the early
studies  of these DAA-based approaches have shown promis-
ing  results for rapid and profound inhibition of HCV RNA, the
efﬁcacy  and safety of such regimens have yet to be established,
especially in complicated cases.8
Another therapeutic strategy that may  overcome the lim-
itations  of cirrhosis-related complications and improve the
efﬁcacy  of antiviral therapies is pre-emptive splenectomy.9,10However, this alternative treatment remains largely theoreti-
cal  and its appropriateness is controversial. This clinical study
was  designed to prospectively investigate the safety and efﬁ-
cacy  of prior splenectomy for improving antiviral therapeuticeffects  in decompensated cirrhosis patients with HCV infec-
tion.
This  study was  approved by the Institutional Ethics Com-
mittee  of the Second Afﬁliated Hospital of the College
of  Medicine at Xi’an Jiaotong University (March 20, 2008).
Between January 2008 and January 2011, patients diagnosed
with  HCV-related decompensated cirrhosis were recruited to
the study according to the following eligibility criteria: no
prior  antiviral therapeutic intervention; adequate liver func-
tion  (Child-Pugh class A or B); thrombocytopenia (platelet
count:  <80 × 103 L−1); severe esophagogastric varices with
or  without variceal bleeding; no severe comorbidities, such
as  hepatocellular carcinoma or chronic renal failure. The
diagnosis  of decompensated liver cirrhosis was  made when
a  patient had experienced one or more  of the following
clinical symptoms: ascites, variceal bleeding, spontaneous
bacterial peritonitis (SBP), and encephalopathy. Of the 1092
consecutively admitted cirrhotics, 198 were excluded for
hepatocellular carcinoma, 710 for non-HCV-related disease
(586  HBV, 65 alcoholic, 58 biliary cirrhosis and one patients
with  haemochromatosis), 37 for inadequate liver function
(Child-Pugh class C), 28 for chronic invalidating disease (such
as  unstable cardiovascular disease, chronic renal failure, or
severe chronic obstructive lung disease), 23 for being older
than  65 years, 5 for previous combination antiviral ther-
apy,  28 for refusing to be treated, and 50 patients with
moderate hypersplenism and portal hypertension received
pegylated/standard IFN- plus ribavirin combination therapy
with  a low accelerating dosage regimen for 48 weeks (partial
results  has been described in previous study5). The remaining
13  patients were  enrolled into the study. The characteristics of
the  13 patients are presented in Table 1. All the patients were
clearly  informed about the beneﬁts and risks of the therapy.
Written, signed consent was obtained from all participants.
The study was  performed without any ﬁnancial support from
producers  of drugs.
Open  splenectomy with azygoportal disconnection sur-
gical  procedure was  performed as described previously.11
Peripheral blood samples were collected immediately prior to
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urgery and on post-surgery days 1, 3, 7, 10 and one-month for
outine monitoring of patient status and analysis of biomark-
rs  of HCV infection and liver function. When platelet counts
xceeded  300,000/L, aspirin was  administered. Abdominal
ltrasound was  performed between post-surgery days 7 and
0  to assess portal vein thrombosis (PVT). When PVT occurred,
arfarin  was  administered.
For  all patients, antiviral treatment was  initiated at one to
hree  months after splenectomy. The 48-week combination
herapy regimen was assigned according to the HCV genotype.
atients  infected with HCV genotype 2a were treated with
he  combination of standard (non-pegylated) IFN-2b (3 MU
ubcutaneous injections, thrice weekly) plus ribavirin (800 mg
rally, daily). For nine patients infected with HCV genotype
b,  two patients received PEG IFN-2a (180 g subcutaneous
njections, once weekly), three patients received PEG IFN-
b  (1.5 g/kg subcutaneous injections, once weekly) and the
ther  four patients received standard IFN-2b (3 MU subcuta-
eous  injections, thrice weekly) in combination with ribavirin
800  mg  orally for patients weighing < 60 kg and 1000 mg  orally
or  patients weighing > 60 kg, daily) for 48 weeks. Patients were
onitored  for drug-related complications, such as cytope-
ia,  to facilitate timely dose reductions or discontinuation
f antiviral treatment. Patients were routinely monitored
or  SVR, relapse, partial and null response according to the
ccepted  guidelines.12
All data values are expressed as mean ± standard devia-
ion.  Statistical comparisons between pre- and post-operative
ata  were  made using paired t-test. A p-value of <0.05 was
onsidered statistically signiﬁcant.
Of the 13 patients who  received splenectomy with azy-
oportal disconnection in this study, four had previously
nderwent abdominal surgery, including cholecystectomy
n = 2), uterine-incision delivery (n = 1), and enterectomy (n = 1).
he mean surgical duration of the splenectomy procedure was
93  ± 27.5 min  (range: 160–260 min), and the mean blood loss
as  163 ± 65 mL  (range: 100–340 mL). All patients survived and
one  experienced infectious complications. Minor PVT was
etected  by ultrasound in two patients, and eight patients
eveloped transient ascites. Histologic evaluation of the
esected  spleen specimens showed congestive splenomegaly
n  all 13 patients.
As  shown in Table 2, some of the liver function mark-
rs  were  improved at one-month after splenectomy. The
hild-Pugh class improved for 5 patients but remained
nchanged for the remaining 8 patients. The pooled
Table 2 – Liver function markers before and one month after sp
Marker Before 
STB, mol/L 22.83 ± 8.60 
ALT, IU/L 57.77 ± 41.52 
Serum albumin, g/dL 36.84 ± 2.49 
PTA, % 71.55 ± 10.44 
Mild ascites, n 2 
Encephalopathy, n 0 
CPS 6.00 ± 1.00 
STB, serum total bilirubin; ALT, alanine transaminase; PTA, prothrombin t3;1 7(5):601–605  603
average Child-Pugh class score at one-month was  not
signiﬁcantly different from baseline. However,  serum ala-
nine  transaminase levels were moderately elevated in the
majority  of patients, and the mean level at one-month
was signiﬁcantly higher than that at baseline. Signiﬁcant
increases were also observed in mean platelet count (one-
month  post-splenectomy: 186.0 ± 70.62 × 103 L−1 vs. base-
line:  48.23 ± 15.92 × 103 L−1, p < 0.001), mean leukocyte count
(5.695  ± 1.423 vs. 2.102 ± 0.492 × 103 L−1, p < 0.001) and mean
neutrophil count (2.045 ± 0.674 vs. 0.977 ± 0.203 × 103 L−1,
p  < 0.001).
All 13 patients completed 48 weeks of antiviral therapy
and  at least 24 weeks of follow-up. However, one case (patient
5#)  required a 2-week suspension after 23 weeks of combina-
tion  therapy with PEG-IFN-2a and ribavirin while a severe
intestinal infection was  treated, and three other patients
required a dosage reduction of standard IFN-2b (patient
9#)  and ribavirin (patient 4# and 8#). None of the patients
withdrew from the study due to cytopenia or any other com-
plications  during antiviral treatment. SVR was  achieved in all
four  patients infected with genotype 2a (100%) and in four
of  the nine patients infected with genotype 1b (44%). Among
the  remaining ﬁve patients who did not achieve SVR, three
relapsed,  one showed only a partial response, and one showed
a  null response. Therapeutic outcomes of all 13 patients are
presented  in Table 1. No patients experienced variceal bleed-
ing  or encephalopathy during antiviral treatment or during the
median  19 (range 7–32) months of follow-up off-therapy. There
was  no death or a need for liver transplant, although patient
9#  and patient 4# experienced new episode of SBP and ascites
in  9 and 18 month after end-of-treatment, respectively.
Patients with HCV-related decompensated cirrhosis are
associated  with poor prognosis. This difﬁcult-to-treat popu-
lation  was  recently identiﬁed as appropriate for IFN--based
antiviral therapy.4,7,12 However, the common complication of
severe  thrombocytopenia has proven to be a contraindica-
tion for IFN and ribavirin drugs. In a preliminary prospective
study, we  had evaluated the efﬁcacy and safety of standard
IFN-/ribavirin combination therapy with a low accelerating
dosage regimen for HCV-related decompensated cirrhosis.5
Even though by the end of treatment 66.7% of the examined
patients had undetectable level of HCV RNA and improved
liver  function, 50% of those patients eventually relapsed.5We  speculated that this high relapse rate could be related to
inadequate  dose and/or therapy duration. In addition, 25% of
those  patients experienced severe adverse events, including
lenectomy (n = 13).
After (one month later) p-Value
18.75 ± 9.06 0.115
91.23 ± 52.64 0.006
37.30 ± 4.68 0.669
78.41 ± 10.25 0.035
0 NA
0 NA
5.85 ± 0.69 0.337
ime activity; CPS, Child-Pugh score; NA, not applicable.
i s . 2 0
This work was  supported by National Natural Science Foun-
dation  of China (No. 30901268) and The Health Research604  b r a z j i n f e c t d 
severe thrombocytopenia with extensive hemorrhage, SBP,
and  variceal bleeding,5 which is a major cause of death in
cirrhotic  patients. Considering these results, we  speculated
that  a pre-emptive treatment strategy, to overcome the initial
complications, might help improving the efﬁcacy of subse-
quent  antiviral therapy. Thus, we  designed the current study
to  investigate the efﬁcacy and safety of open splenectomy
and azygoportal disconnection to reverse thrombocytopenia
and improve subsequent antiviral therapy in selected patients
with  HCV-related decompensated cirrhosis.
The current study, which included nine patients classi-
ﬁed  as Child-Pugh grade A and four patients classiﬁed as
Child-Pugh grade B, indicated that this pre-emptive strategy
was  safe. Only two patients developed minor PVT, which was
completely  resolved in one patient by a two-week course of
warfarin.  All patients showed improved or unchanged liver
function  by one month after surgery, which is remarkable
considering that eight patients experienced transient ascites.
These  ﬁndings agree with previous reports of splenectomized
patients showing a small decrease in the mean model of
end-stage  liver disease (MELD) score and/or Child-Pugh score
following  surgery.9–11 In the current study, splenectomized
patients also showed a normalized level of platelet and leuko-
cyte  counts that was  sustained for one-month after surgery,
thereby  allowing these patients to undergo subsequent antivi-
ral  therapy without hematologic disturbance. All 13 study
participants underwent full-dose pegylated or standard IFN-
  therapy with ribavirin, which was  initiated within one
to  three months after the splenectomy surgery. Only one
of  those patients required transient IFN- interruption to
address  a severe intestinal infection and a few others required
reduced  antiviral dosages. Importantly, no patient required
premature treatment withdrawal and all patients completed
the  48-week course without developing variceal bleeding or
encephalopathy and while remaining complication-free dur-
ing the 24-week follow-up.
Another  intriguing ﬁnding from the current study was  that
100%  (4/4) of HCV genotype 2-infected patients achieved SVR
while  less than 50% (4/9) of HCV genotype 1-infected patients
achieved  SVR. Although the number of eligible cases examined
was  exceedingly small, the antiviral treatment results are sim-
ilar to those previously reported for larger cohorts of patients
without  thrombocytopenia,13,14 suggesting that splenectomy
does not reduce the antiviral efﬁcacy of IFN-based treatment.
The  pre-emptive strategy of splenectomy for patients with
HCV-related cirrhosis to facilitate antiviral therapy has not
been  practiced widely. Very few studies to date have pro-
vided  evidence that splenectomy would be conducive to
eradicate  the virus in addition to improving thrombocy-
topenia and leukocytopenia.15,16 In one study by Sekiguchi
et  al., splenectomized HCV-related cirrhotic patients were
shown  to experience decreased virus burden through aug-
mentation  of their natural killer cell activity.15 In another
study by Hashimoto et al., the splenectomy procedure
was  demonstrated to facilitate viral clearance by inducing
recovery of IFN- production and peripheral CD4+ T cell
16proliferation. Certainly, any effect on the immune system
that  are induced upon splenectomy could help establishing
a  beneﬁcial milieu for the antiviral mechanisms of IFN-
and  ribavirin. For example, peripheral tolerance is partially 1 3;1  7(5):601–605
promoted by splenic-induced up-regulation of programmed
death-1 (PD-1) ligands, and the fact that splenectomy is fol-
lowed  by a reduction in PD-1-expressing CD4+ T cells in
peripheral blood may  explain the enhanced eradication of
HCV.16
Another important aspect of the current study is the Asian
ancestry  of the patient population. Asians have a signiﬁ-
cantly higher probability of viral response than Caucasians
and  Africans,17,18 and this character has been attributed to
genetic  variants in the interleukin (IL)-28B gene.18,19 None of
our  patients underwent IL-28B genotyping, and future stud-
ies  of pre-emptive splenectomy should assess the potential
contribution of this genotype to the SVR rates achieved. It is
possible  that a particular IL-28B variant may  identify a pop-
ulation  of patients that are likely to beneﬁt most from this
pre-emptive surgical strategy, so that genotyping may  be a
useful method to avoid the burden and cost of unnecessary
surgery.
Recently, a triple combination therapy of ﬁrst-generation
protease inhibitors plus PEG-IFN and ribavirin has been
administered to compensated cirrhosis patients with HCV
genotype  1 infection.20 However, its feasibility for treating
patients who have reached the decompensated stage remains
unknown.  Preliminary results with the protease inhibitors
telaprevir or boceprevir have been promising, which leads
us  to speculate that such a broader range combination ther-
apy  regimen may  further beneﬁt the pre-emptive splenectomy
strategy for treating various cirrhotic patients with genotype
1  and high viral loads.
There  are some limitations in our study: small sample size,
observational study, no standard-of-care antiviral treatment
in  all patients, not compared to patients without treatment,
short  follow up, etc. Despite these limitations, several conclu-
sions  can be drawn based upon careful consideration of the
available  data.
Splenectomy and azygoportal disconnection may  repre-
sent  a safe and effective strategy for improving thrombocy-
topenia, reducing the risk of esophagogastric varices bleeding,
and  promoting efﬁcacy of subsequent antiviral therapy in
selected  HCV-related cirrhosis patients with portal hyperten-
sion  and hypersplenism. Further investigations with larger
cohorts  of patients are required to conﬁrm the feasibility of
this  procedure in clinical application and uncover its underly-
ing  mechanisms.
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